Development of a novel anti-HER2 monoclonal antibody H2Mab-181 for gastric cancer

Junko Takei, Teizo Asano, Tomohiro Tanaka, Masato Sano, Hideki Hosono, Ren Nanamiya, Nami Tateyama, Masaki Saito, Hiroyoshi Suzuki, Hiroyuki Harada, Mika K. Kaneko, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Human epidermal growth factor receptor 2 (HER2) is a type I transmembrane 185 kDa protein. HER2 is expressed in a variety of normal tissue types and cancer cells. HER2 is associated with cell proliferation, differentiation, and migration. The overexpression of HER2 has been observed in a number of cancers, including breast and gastric cancers. Gastric cancer is one of the most common cancers worldwide, with an annual case rate of ∼1 million people diagnosed with the disease. Trastuzumab is a humanized anti-HER2 monoclonal antibody (mAb) that has been utilized in gastric cancer therapy. In this study, we have developed a novel anti-HER2 mAb, H2Mab-181 (IgG1, kappa), through the immunization of mice with a purified recombinant extracellular domain of HER2. H2Mab-181 can specifically and sensitively detect HER2 in both flow cytometry and Western blot applications in gastric cancer cell lines and can also be utilized in immunohistochemical analyses of gastric cancer tissues. Together, H2Mab-181 could be useful for the diagnosis and therapy in gastric cancers.

Original languageEnglish
Pages (from-to)168-176
Number of pages9
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Issue number4
Publication statusPublished - 2021 Aug 1


  • HER2
  • gastric cancer
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Development of a novel anti-HER2 monoclonal antibody H2Mab-181 for gastric cancer'. Together they form a unique fingerprint.

Cite this